Skip to content
value.today

Precision Biologics, Inc.

🇺🇸 Great Neck, New York, USABiotechnologyFounded 2012
Total raised
$66 M
3 rounds on record
Latest round
$53 M
Oct 2015
First round on record
Mar 2013
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Precision Biologics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2015$53 MNo. 3$50 to $250 million

Precision Biologics, Inc.: Raise no. 3, Oct 2015

Investors in this round

34 investors had bought by the notice of Oct 19, 2015: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$53 M of $53 M offered
Smallest investment taken
$50,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Philip M. Arlen · Executive Officer, Director
  • R.J. B. Childress · Executive Officer
  • Charles M. Kim · Director
  • Christian M. Zapf · Director
  • Patrick M. Soon-Shiong · Director
  • Stanley B. Archibald, Jr. · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Philip M. Arlen, President. Source: SEC Form D, newest notice filed Oct 19, 2015. Read the notice at the SEC.

equitySEC
Nov 2013$11 MNo. 2$10 to $50 million

Precision Biologics, Inc.: Raise no. 2, Nov 2013

Investors in this round

14 investors had bought by the notice of Dec 16, 2013: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $13 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Albine K Martin · Executive Officer
  • Philip M Arlen · Executive Officer
  • R.J. B Childress · Executive Officer
  • Robert A Washington · Executive Officer
  • C. Brent Haggard · Director
  • Mark B Kristen · Director
  • Severin B Russo · Director
  • Sheldon B Rabin · Director
  • Stanley B Archibald, Jr. · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering for 150,000 options per investor as consideration for execution of limited guaranty. Company receives no proceeds from offering but up to $5 per share if options exercised. All proceeds up to amount of limited guaranty to pay down line of credit”

Signed by Philip M. Arlen, President. Source: SEC Form D, newest notice filed Dec 16, 2013. Read the notice at the SEC.

optionsSEC
Mar 2013$2 MNo. 1$2 to $10 million

Precision Biologics, Inc.: Raise no. 1, Mar 2013

Investors in this round

85 investors had bought by the notice of May 21, 2013: 85 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Albine K Martin · Executive Officer
  • Philip M Arlen · Executive Officer
  • R.J. B Childress · Executive Officer
  • Robert A Washington · Executive Officer
  • C. Brent Haggard · Director
  • Mark B Kristen · Director
  • Severin B Russo · Director
  • Sheldon B Rabin · Director
  • Stanley B Archibald, Jr. · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Philip M. Arlen, President and CEO. Source: SEC Form D and 1 amendment, newest notice filed May 21, 2013. Read the notice at the SEC.

equitySEC
Sep 2012$5 MIssued in a merger or acquisition$2 to $10 million

Precision Biologics, Inc.: Private sale, Sep 2012

Investors in this round

30 investors had bought by the notice of Oct 11, 2012: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
$75,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Albine K Martin · Executive Officer
  • Philip M Arlen · Executive Officer
  • R.J. B Childress · Executive Officer
  • Robert A Washington · Executive Officer
  • Mark B Kristen · Director
  • Severin B Russo · Director
  • Sheldon B Rabin · Director
  • Stanley B Archibald, Jr. · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Acquisition of the assets of Neogenix Oncology, Inc. pursuant to Section 363 of the Bankruptcy Code.”

Signed by Philip M. Arlen, President and CEO. Source: SEC Form D, newest notice filed Oct 11, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Precision Biologics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2015).

    SEC Form D · Oct 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2015

That is all the official record says: Precision Biologics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Precision Biologics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 85 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Precision Biologics, Inc.
NameRoleNamed in
Philip M. ArlenExecutive officerOct 2015
R.J. B. ChildressExecutive officerOct 2015
Albine K MartinExecutive officerDec 2013
Philip M ArlenExecutive officerDec 2013
R.J. B ChildressExecutive officerDec 2013
Robert A WashingtonExecutive officerDec 2013
Charles M. KimDirectorOct 2015
Christian M. ZapfDirectorOct 2015
Patrick M. Soon-ShiongDirectorOct 2015
Philip M. ArlenDirectorOct 2015
Stanley B. Archibald, Jr.DirectorOct 2015
C. Brent HaggardDirectorDec 2013
Mark B KristenDirectorDec 2013
Severin B RussoDirectorDec 2013
Sheldon B RabinDirectorDec 2013
Stanley B Archibald, Jr.DirectorDec 2013
Stanley B. Archibald, Jr.PromoterOct 2015
Stanley B Archibald, Jr.PromoterDec 2013